Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Deferred Taxes (2021 - 2025)

Collegium Pharmaceutical (COLL) has 5 years of Deferred Taxes data on record, last reported at -$10.1 million in Q4 2025.

  • For Q4 2025, Deferred Taxes rose 0.83% year-over-year to -$10.1 million; the TTM value through Dec 2025 reached -$25.7 million, up 4.31%, while the annual FY2025 figure was -$25.7 million, 4.31% up from the prior year.
  • Deferred Taxes reached -$10.1 million in Q4 2025 per COLL's latest filing, up from -$12.1 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $2.1 million in Q3 2022 and bottomed at -$62.6 million in Q2 2021.
  • Average Deferred Taxes over 5 years is -$7.4 million, with a median of -$3.4 million recorded in 2022.
  • Peak YoY movement for Deferred Taxes: surged 656.23% in 2022, then plummeted 9491.3% in 2024.
  • A 5-year view of Deferred Taxes shows it stood at -$15.0 million in 2021, then skyrocketed by 92.82% to -$1.1 million in 2022, then surged by 68.65% to -$338000.0 in 2023, then crashed by 2904.73% to -$10.2 million in 2024, then grew by 0.83% to -$10.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Deferred Taxes were -$10.1 million in Q4 2025, -$12.1 million in Q3 2025, and -$2.9 million in Q2 2025.